Article No
ANC-174-820
anti-CD25 (human), mAb (7G7B6) (preservative free)
anti-CD25 (human), mAb (7G7B6) (preservative free)
Antibodies Primary
Specifications
| Application | FC, IHC |
| Article No | ANC-174-820 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Clone | 7G7B6 |
| Clone Type | monoclonal |
| Conjugation | Unconjugated |
| Description | anti-CD25 (human), mAb (7G7B6) (preservative free) |
| Supplier | Adipogen Life Sciences |
| Format | Liquid |
| Immunogen | Stimulated PBMC. |
| Isotype | IgG2a |
| Notes | Expression of human CD25 (the alpha subunit of the IL-2 receptor complex) is dramatically upregulated on activated T cells, B cells, NK cells and macrophages. Antibodies to CD25 are being studied for potential use as an immunodirected therapy to selectively attack (kill) CD25 expressing cells.|Monoclonal Antibody. Isotype: Mouse IgG2a. Clone: 7G7B6. Applications: FACS, IHC. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl Expression of human CD25 (the alpha subunit of the IL-2 receptor complex) is dramatically upregulated on activated T cells, B cells, NK cells and macrophages. Antibodies to CD25 are being studied for potential use as an immunodirected therapy to selectively attack (kill) CD25 expressing cells. |
| Alias Names | IL-2 Receptor Subunit alpha; IL-2-RA; TAC Antigen; p55 |
| Product Type | Antibodies Primary |
| Research area | Immunology |
| Shipping Information | BLUE ICE |
| Size | 100 µg |
| Source / Host | mouse |
| Species Reactivity | human |
| Stability | Stable for at least 1 year after receipt when stored at +4°C. |
| Storage | 4°C |
| Substrate / Buffer | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl |
| Technical Specifications | Monoclonal Antibody. Isotype: Mouse IgG2a. Clone: 7G7B6. Applications: FACS, IHC. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl Expression of human CD25 (the alpha subunit of the IL-2 receptor complex) is dramatically upregulated on activated T cells, B cells, NK cells and macrophages. Antibodies to CD25 are being studied for potential use as an immunodirected therapy to selectively attack (kill) CD25 expressing cells. |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
